LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rhosin Blocks the Stimulating Activity of RhoA in Breast Cancer Cells

By LabMedica International staff writers
Posted on 10 Jul 2012
Print article
The candidate low molecular weight drug Rhosin was found to have pronounced effects on in vitro breast cancer cell cultures as well as on cultures of neuronal cells.

Rhosin was discovered by investigators at the Cincinnati Children's Hospital Medical Center (Ohio, USA) who coupled advanced high-throughput molecular screening with computerized drug design software to identify a druggable target site on the critical protein component of the Rho GTPase signaling complex, RhoA.

RhoA is essential for the signaling function of the Rho GTPase complex. Previous studies have shown that in breast cancer increased RhoA activity stimulated cancer cell invasiveness and spreading, while RhoA deficiency suppressed cancer growth and progression. In addition to its role in breast cancer, imbalance in Rho GTPas activity has been implicated in other human diseases, including various cancers and neurological disorders.

In the current study, which was published in the June 21, 2012, online edition of the journal Chemistry & Biology, the investigators treated breast cancer and neuronal cell cultures with Rhosin. They reported that Rhosin specifically inhibited RhoA activity and RhoA-mediated cellular function without affecting other signaling activities. By suppressing RhoA activity, Rhosin inhibited mammary sphere formation by breast cancer cells and inhibited invasion of mammary epithelial cells. In the neuronal cell cultures, Rhosin induced neurite outgrowth of PC12 cells in synergy with nerve growth factor (NGF).

"Although still years from clinical development, in principle Rhosin could be useful in therapy for many kinds of cancer or possibly neuron and spinal cord regeneration," said senior author Dr. Yi Zheng, professor of experimental hematology and cancer biology at Cincinnati Children's Hospital Medical Center. "We have performed in silica rational drug design, pharmacological characterization, and cell tests in the laboratory, and we are now starting to work with mouse models."

Related Links:

Cincinnati Children's Hospital Medical Center



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more